National Account Director, Government Payers —Medicaid

National Account Director, Government Payers —Medicaid

Remote-Field (US)

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

HARMONi:
Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3:
Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first‑line metastatic NSCLC.

HARMONi-7:
Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first‑line metastatic NSCLC.

HARMONi-GI3:
Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

The National Accounts Director, Government Payers –Medicaid willbe responsible for leadership and management of Fee-for-Service Medicaid, Managed Medicaid, and Medicaid Buying Pools and other assigned accounts. This is a critical customer‑facing role helping to ensure broad access, reimbursement, and patient affordability.

The Director willbe responsible for building andmaintainingstrong relationships with decision makers within the accounts, including medical and pharmacy departments. This role involves executing strategies and tactics within each account, while also providing support to the regional field matrix teams when necessary.

A strong understanding of managed markets, reimbursement, and payer account management is essential.

• Establish andmaintainrelationships with key decision makers, including P&T, Medical and Pharmacy Director, and population-based stakeholders to secure appropriate accessandoptimalproduct positioning.
• Build the state Medicaid access strategy across fee‑for‑service programs, Medicaid managed care organizations, and single preferred drug list states, prioritizing oncology volume, coveragerestrictivenessand state dynamics.
• Navigate state‑levelutilizationmanagement: prior authorization criteria, step edits, preferred drug lists, P&T committee submissions, and state Drug Utilization Review boards.
• Address physician‑administered drug billing requirements at the state level, including NDC‑to‑HCPCS crosswalk requirements and state‑specific claims mechanics that create access friction for buy‑and‑bill products.
• Monitor Medicaid policy developments — state budget pressure, supplemental rebate arrangements,…